A Phase II Efficacy Study Comparing 2',3'-Dideoxyinosine (ddI) (BMY-40900) and Zidovudine Therapy of Patients With HIV Infection Who Have Been on Long Term Zidovudine Treatment
NCT ID: NCT00000671
Last Updated: 2011-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
750 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC. However, AZT therapy has been associated with significant toxicities. In addition, the effectiveness of AZT appears to decrease during the second and third years of therapy. For these reasons, the development of alternative therapy that would be at least as effective but less toxic is of great importance. The drug ddI is an antiviral agent that inhibits replication of HIV with less apparent toxicity than AZT. Studies indicate that ddI remains active in the body for at least 12 hours; thus benefits of ddI might be achieved with a low frequency of drug administration.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of ddI Versus Zidovudine in HIV-Infected Patients
NCT00000979
Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
NCT00002035
A Randomized, Double Blind, Comparative Study of Dideoxycytidine (ddC) Alone or ddC/AZT Combination Versus Zidovudine (ZDV) Alone in Patients With HIV Infection Who Have Received Prior ZDV Therapy
NCT00000651
A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex
NCT00000710
An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex
NCT00000672
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two dose levels of ddI, each adjusted depending on patient's weight at study entry, are compared with a variable dosage regimen of AZT (the dose which the patient is tolerating at the time of study entry). Randomization is stratified by baseline CD4 cell count (less than 100 or 100-300) and Medical Center. This study continues for at least 12 months after the entry of the first subject. Patients randomized to AZT will receive orally. All patients randomized to AZT also receive a ddI placebo at 12 hour intervals. Patients randomized to ddI receive AZT placebo.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zidovudine
Didanosine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Required:
* Aerosolized pentamidine (300 mg every 4 weeks).
Allowed:
* Chronic suppressive treatment for toxoplasmosis, Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis, herpes simplex virus infection.
* Ganciclovir for patients developing cytomegalovirus (CMV) infection while in study.
* Erythropoietin for patients under the relevant treatment IND.
* Treatment of opportunistic infections with other than sulfonamide-containing regimens.
* Aspirin, acetaminophen, or non-steroidal anti-inflammatory agents is discouraged, but is permitted for as short a period of time as possible.
* Chronic use of trimethoprim - sulfamethoxazole or other sulfonamide preparations is not encouraged while on study.
Patients must:
* Have had the diagnosis of AIDS or advanced AIDS related complex (ARC).
* Have received AZT therapy for at least 12 months, with a minimal daily dose of 500 mg/day and with no more than 60 days off AZT therapy within the 12 month period; medical records with documentation of AZT dosing must be provided.
* Provide informed consent (guardian as appropriate).
* Be available for follow-up for at least 6 months.
* Have the inclusion laboratory values within approximately 14 days of initiating therapy (except for CD4 cell counts).
* Patients whose AIDS-defining condition is Kaposi's sarcoma alone must have CD4 cell counts \< 300 cells/mm3.
Allowed:
* Positive blood culture for Mycobacterium avium or Cytomegalovirus.
* Prior history of toxoplasmosis, Herpes simplex, Cryptococcus, or Pneumocystis carinii pneumonia (PCP) requiring chronic suppressive therapy.
* Occasional premature atrial or ventricular contractions.
Prior Medication:
Required:
* Zidovudine (AZT) therapy for at least 12 months, with a minimal daily dose of 500 mg/day, and with no more than 60 days off AZT therapy within the 12-month period (documentation of AZT dosing must be provided).
Allowed:
* Intralesional agents.
Exclusion Criteria
Patients with the following are excluded:
* Psychological or emotional problems sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy.
* AIDS-dementia complex = or \> stage 2.
* Active AIDS defining opportunistic infections not specifically allowed.
* Intractable diarrhea.
* Grade 2 neuropathy, based on the Neuropathy Targeted Symptom Questionnaire, or any moderate abnormality indicative of peripheral neuropathy, particularly impaired sensation of sharp pain, light touch, or vibration in the lower extremities, distal extremity weakness, or distal extremity hyperreflexia.
* Prior history of acute pancreatitis within past 2 years or chronic pancreatitis.
* History of seizures within past 2 years or currently requiring anticonvulsants for control.
* History of past or current heart disease.
* Malignancy likely in the investigator's opinion to require cytotoxic chemotherapy during the expected course of this trial.
* Life expectancy \< 3 months.
Concurrent Medication:
Excluded:
* Isoniazid (INH). Neurotoxic drugs. Oral acidifying agents.
Patients with the following are excluded:
* Psychological or emotional problems sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy.
* AIDS-dementia complex = or \> stage 2.
* Active AIDS defining opportunistic infections not specifically allowed.
* Intractable diarrhea.
* Prior history of acute pancreatitis within past 2 years or chronic pancreatitis.
* History of seizures within past 2 years or currently requiring anticonvulsants for control.
* History of past or current heart disease.
* Malignancy likely in the investigator's opinion to require cytotoxic chemotherapy during the expected course of this trial.
* Life expectancy = or \< 3 months.
* Previous participation in any study of ddI, ddC or d4T.
Prior Medication:
Excluded:
* Ganciclovir (DHPG).
* Excluded within 1 month of study entry:
* ddI and any other antiretroviral drug or investigational anti-HIV agent except for zidovudine (AZT).
Interferons.
* Immunomodulating drugs.
* Cytotoxic agents not specifically allowed.
* Neurotoxic drugs.
Excluded within 3 months of study entry:
* Ribavirin.
Prior Treatment:
Excluded within 14 days of study randomization:
* Blood transfusion.
Active alcohol or drug abuse that is sufficient, in investigator's opinion, to prevent adequate compliance with study therapy.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
J Kahn
Role: STUDY_CHAIR
D Richman
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Children's Hosp of Los Angeles/UCLA Med Ctr
Los Angeles, California, United States
Los Angeles County - USC Med Ctr
Los Angeles, California, United States
Cedars Sinai / UCLA Med Ctr
Los Angeles, California, United States
UCLA CARE Ctr
Los Angeles, California, United States
Harbor - UCLA Med Ctr / UCLA School of Medicine
Los Angeles, California, United States
Palo Alto Veterans Adm Med Ctr / Stanford Univ
Palo Alto, California, United States
Univ of California / San Diego Treatment Ctr
San Diego, California, United States
San Francisco AIDS Clinic / San Francisco Gen Hosp
San Francisco, California, United States
Stanford at Kaiser / Kaiser Permanente Med Ctr
San Francisco, California, United States
Stanford Univ School of Medicine
Stanford, California, United States
Olive View Med Ctr
Sylmar, California, United States
Sepulveda Veterans Adm Med Ctr / Olive View Med Ctr
Sylmar, California, United States
Harbor UCLA Med Ctr
Torrance, California, United States
Mountain States Regional Hemophilia Ctr / Univ of Colorado
Denver, Colorado, United States
Univ of Colorado Health Sciences Ctr
Denver, Colorado, United States
George Washington Univ Med Ctr
Washington D.C., District of Columbia, United States
G E Morey Jr
Fort Lauderdale, Florida, United States
Univ of Miami School of Medicine
Miami, Florida, United States
Northwestern Univ Med School
Chicago, Illinois, United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, United States
Edward Hines Veterans Administration Hosp
Hines, Illinois, United States
Indiana Univ Hosp
Indianapolis, Indiana, United States
Univ of Kansas School of Medicine
Wichita, Kansas, United States
Louisiana Comprehensive Hemophilia Care Ctr
New Orleans, Louisiana, United States
Louisiana State Univ Med Ctr / Tulane Med School
New Orleans, Louisiana, United States
Tulane Univ School of Medicine
New Orleans, Louisiana, United States
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts, United States
Boston Med Ctr
Boston, Massachusetts, United States
Beth Israel Deaconess - West Campus
Boston, Massachusetts, United States
Beth Israel Deaconess Med Ctr
Boston, Massachusetts, United States
Baystate Med Ctr of Springfield
Springfield, Massachusetts, United States
Med Ctr of Central Massachusetts
Worcester, Massachusetts, United States
Univ of Massachusetts Med Ctr
Worcester, Massachusetts, United States
Univ of Minnesota
Minneapolis, Minnesota, United States
Nebraska Regional Hemophilia Ctr
Omaha, Nebraska, United States
SUNY / Erie County Med Ctr at Buffalo
Buffalo, New York, United States
City Hosp Ctr at Elmhurst / Mount Sinai Hosp
Elmhurst, New York, United States
Beth Israel Med Ctr / Peter Krueger Clinic
New York, New York, United States
Bellevue Hosp / New York Univ Med Ctr
New York, New York, United States
Cornell Univ Med Ctr
New York, New York, United States
Mem Sloan - Kettering Cancer Ctr
New York, New York, United States
Saint Luke's - Roosevelt Hosp Ctr
New York, New York, United States
Mount Sinai Hemophilia Ctr / Mount Sinai Med Ctr
New York, New York, United States
Mount Sinai Med Ctr
New York, New York, United States
Univ of Rochester Medical Center
Rochester, New York, United States
SUNY - Stony Brook
Stony Brook, New York, United States
SUNY / State Univ of New York
Syracuse, New York, United States
Bronx Municipal Hosp Ctr/Jacobi Med Ctr
The Bronx, New York, United States
Jack Weiler Hosp / Bronx Municipal Hosp
The Bronx, New York, United States
Montefiore Med Ctr / Bronx Municipal Hosp
The Bronx, New York, United States
Bronx Veterans Administration / Mount Sinai Hosp
The Bronx, New York, United States
Univ of North Carolina
Chapel Hill, North Carolina, United States
Duke Univ Med Ctr
Durham, North Carolina, United States
Bowman Gray School of Medicine / Wake Forest Univ
Winston-Salem, North Carolina, United States
Holmes Hosp / Univ of Cincinnati Med Ctr
Cincinnati, Ohio, United States
Univ Hosp of Cleveland / Case Western Reserve Univ
Cleveland, Ohio, United States
Ohio State Univ Hosp Clinic
Columbus, Ohio, United States
Med College of Ohio
Toledo, Ohio, United States
Milton S Hershey Med Ctr
Hershey, Pennsylvania, United States
Univ of Pennsylvania
Philadelphia, Pennsylvania, United States
Hemophilia Ctr of Western PA / Univ of Pittsburgh
Pittsburgh, Pennsylvania, United States
Univ of Pittsburgh Med School
Pittsburgh, Pennsylvania, United States
Julio Arroyo
West Columbia, South Carolina, United States
Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr
Knoxville, Tennessee, United States
Hermann Hosp / Univ Texas Health Science Ctr
Houston, Texas, United States
Dr Stephen L Green
Hampton, Virginia, United States
Univ of Washington
Seattle, Washington, United States
Dr Brian Buggy
Milwaukee, Wisconsin, United States
Milwaukee County Med Complex
Milwaukee, Wisconsin, United States
Great Lakes Hemophilia Foundation
Milwaukee, Wisconsin, United States
San Juan Veterans Administration Med Ctr
San Juan, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Smith MS, Koerber KL, Pagano JS. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. J Infect Dis. 1994 Jan;169(1):184-8. doi: 10.1093/infdis/169.1.184.
Bozzette SA, Hays RD, Berry SH, Kanouse DE. A Perceived Health Index for use in persons with advanced HIV disease: derivation, reliability, and validity. Med Care. 1994 Jul;32(7):716-31. doi: 10.1097/00005650-199407000-00005.
Fiscus SA, Heggem-Snow A, Troiani L, Wallmark E, Folds JD, Sheff B, van der Horst CM. Transient high titers of HIV-1 in plasma and progression of disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 May 1;9(1):51-7.
Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CS, Kahn J. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis. 1996 Oct;174(4):704-12. doi: 10.1093/infdis/174.4.704.
Richardson D, Liou SH, Kahn JO. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117. J Acquir Immune Defic Syndr (1988). 1993 Nov;6(11):1212-23.
Kozal M, Winters M, Shafer R, Kroodsma K, Katzenstein D, Merigan T. Behavior of codon 74 and 215 pol gene mutations in 62 AZT experienced patients on ddI monotherapy. Natl Conf Hum Retroviruses Relat Infect (1st). 1993 Dec 12-16;55
Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med. 1994 Aug 15;121(4):263-8. doi: 10.7326/0003-4819-121-4-199408150-00005.
Schooley RT. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs. AIDS. 1995 Dec;9 Suppl 2:S15-S19.
Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992 Aug 27;327(9):581-7. doi: 10.1056/NEJM199208273270901.
Richman DD. Clinical significance of drug resistance in human immunodeficiency virus. Clin Infect Dis. 1995 Oct;21 Suppl 2:S166-9. doi: 10.1093/clinids/21.supplement_2.s166.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
070V1
Identifier Type: -
Identifier Source: secondary_id
AI454-009
Identifier Type: -
Identifier Source: secondary_id
ACTG 117
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.